Biblio
Splenectomy before Allogeneic hematopoietic stem-cell transplantation for myelofibrosis: tumor burden matters!. Am J Hematol. 2020.
. Sonographic Appearance of the Gallbladder in the Allogeneic Hematopoietic Stem Cell Transplant Population. J Ultrasound Med. 2016.
. Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD. JCI Insight. 2023.
Prophylactic maintenance with venetoclax/azacitidine after reduced intensity conditioning allo-transplant for high risk MDS and AML. Blood Adv. 2024.
Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Adv. 2023.
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022.
Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host-disease. J Clin Invest. 2020.
Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016.
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143-153.
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014.
Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in The Modern Years. Biol Blood Marrow Transplant. 2015.
Heightened TLR7 Primes BCR-Activated Cells in Chronic Graft-Versus-Host Disease for Effector Functions. Blood Adv. 2023.
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized double blinded phase 2 trial. Blood Adv. 2021.
Favorable Outcomes Following Allogeneic Transplantation in Adults with Hemophagocytic Lymphohistiocytosis. Blood Adv. 2022.
Expansion, persistence, and efficacy of donor memory-like NK cells infused for post-transplant relapse. J Clin Invest. 2022.
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018.
Donor Chimerism Early after Reduced-intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. Biol Blood Marrow Transplant. 2014.
Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Adv. 2023.
Clinical Features of AKI in the Early Post-Transplant Period Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease. Blood. 2016.
Characterization of oral involvement in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014.
. Cell Therapy Informatics: Updates on the integration of HCT/IEC functionalities into an electronic medical record system in the US to promote efficiency, patient safety, research, and data interoperability. Transplant Cell Ther. 2023.
Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016.
Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma. Biol Blood Marrow Transplant. 2019.